Menu
Menu

SMSRC Strategic Healthcare Investment

Independent, data-driven due diligence for healthcare investors evaluating pharmaceutical opportunities.

Move beyond headline financials. Gain a deep understanding of the commercial fundamentals, market positioning, and long-term scalability of your target investment.

SSHI provides independent, Rx data-driven due diligence support to healthcare investors evaluating pharmaceutical companies for acquisition, minority investment, or strategic partnership. SMSRC’s deep industry expertise and proprietary prescription intelligence enable investors to assess the true commercial strength of a target not just its reported numbers.
Our work is built on the same prescription research infrastructure that has guided India’s top pharma companies for over 15 years now applied to the investment evaluation process.

contact us

SSHI evaluates five critical pillars of a target pharmaceutical company:

  • Market Exposure & Opportunity : A comprehensive review of the company’s presence across key treatment areas and molecules, identifying structurally attractive segments versus areas of high competitive intensity.
  • Portfolio Architecture : Analysis of how brands and business units are organised and executed across regions and prescriber types highlighting concentration risks and brands positioned for future expansion.
  • Brand Strength : Assessment of market relevance, competitive standing, growth momentum, prescriber reach, and performance consistency. Includes a review of product launch choices and innovation alignment.
  • Commercial Execution Capability : Evaluation of sales organisation effectiveness coverage strategy, productivity, and alignment with priority customers benchmarked against relevant peer sets.
  • Value Creation Outlook : A forward-looking view of primary revenue growth drivers, strategic acceleration options, and practical levers available post-investment.
contact us

SSHI delivers a clear, evidence-based investment perspective that enables confident decision-making:

  • An objective, data-driven view of the target’s commercial fundamentals independent of management narratives.
  • Identification of structural growth segments and underserved opportunities within the target’s portfolio.
  • A benchmark view of execution strength relative to comparable peers in the Indian Pharmaceutical Market
  • Risk and upside assessment grounded in real prescription data and industry case examples
  • Actionable strategic recommendations for value creation post-investment

SSHI gives healthcare investors the confidence to act and the intelligence to act wisely.

contact us

Move beyond headline financials. Gain a deep understanding of the commercial fundamentals, market positioning, and long-term scalability of your target investment.

What Is SSHI?

SSHI provides independent, Rx data-driven due diligence support to healthcare investors evaluating pharmaceutical companies for acquisition, minority investment, or strategic partnership. SMSRC’s deep industry expertise and proprietary prescription intelligence enable investors to assess the true commercial strength of a target not just its reported numbers.
Our work is built on the same prescription research infrastructure that has guided India’s top pharma companies for over 15 years now applied to the investment evaluation process.

contact us

What We Assess?

SSHI evaluates five critical pillars of a target pharmaceutical company:

  • Market Exposure & Opportunity : A comprehensive review of the company’s presence across key treatment areas and molecules, identifying structurally attractive segments versus areas of high competitive intensity.
  • Portfolio Architecture : Analysis of how brands and business units are organised and executed across regions and prescriber types highlighting concentration risks and brands positioned for future expansion.
  • Brand Strength : Assessment of market relevance, competitive standing, growth momentum, prescriber reach, and performance consistency. Includes a review of product launch choices and innovation alignment.
  • Commercial Execution Capability : Evaluation of sales organisation effectiveness coverage strategy, productivity, and alignment with priority customers benchmarked against relevant peer sets.
  • Value Creation Outlook : A forward-looking view of primary revenue growth drivers, strategic acceleration options, and practical levers available post-investment.
contact us

What You Get?

SSHI delivers a clear, evidence-based investment perspective that enables confident decision-making:

  • An objective, data-driven view of the target’s commercial fundamentals independent of management narratives.
  • Identification of structural growth segments and underserved opportunities within the target’s portfolio.
  • A benchmark view of execution strength relative to comparable peers in the Indian Pharmaceutical Market
  • Risk and upside assessment grounded in real prescription data and industry case examples
  • Actionable strategic recommendations for value creation post-investment

SSHI gives healthcare investors the confidence to act and the intelligence to act wisely.

contact us

Take the next step

Talk to Us

    Our Project

    Our Project

    Our Project